This study is a randomised and controlled trial that aims to investigate whether Cognitive Remediation Therapy (CRT) can modulate epigenetic mechanisms by changing methylation levels of BDNF gene in patients with Schizophrenia.
Name: Cognitive Remediation Therapy
Description: Mean methylation percentage in CpG island BDNF CpG exon I: located at chr11:27743473-27744564 in the BDNF
Measure: Change in methylation at Cytosine-phosphate-Guanine (CpG) exon Time: Baseline and after 4 monthsDescription: Mean methylation percentage of CpG region BDNF CpG exon IV: located at chr11:27723060-27723294 in exon IV, upstream of the start codon in exon VII
Measure: Change in methylation at CpG exon IV Time: Baseline and after 4 monthsDescription: Total score in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery
Measure: Change in cognition Time: Baseline and after 4 monthsDescription: Total score in Positive and Negative Syndromes Scale (PANSS)
Measure: Change in Symptoms Time: Baseline and after 4 monthsAllocation: Randomized
Parallel Assignment
There is one SNP
It also aims to test whether BDNF valine-66-methionine (Val66Met) polymorphism influences CRT treatment outcome among people with schizophrenia. --- valine-66-methionine ---
It also aims to test whether BDNF valine-66-methionine (Val66Met) polymorphism influences CRT treatment outcome among people with schizophrenia. --- valine-66-methionine --- --- Val66Met ---